Adrenergic Drug Market Analysis

Drug Class (Vasopressors, Bronchodilators, Catecholamine)

Adrenergic drug market from the bronchodilators segment is predicted to hold 50% of the revenue share during the forecast period. As a class of drug, bronchodilators promote breathing by expanding the bronchi and relaxing the muscles in the lungs. They're frequently employed to treat long-term illnesses including asthma, a common lung ailment brought on by inflammation of the airways, where the airways may become narrowed and inflammatory. Hence, with the growing prevalence of asthma the segment is set to experience the highest growth. Over 300 million people globally are affected by asthma, which has a significant morbidity and mortality rate. Additionally, individuals with asthma are more inclined to suffer from atopic dermatitis (eczema) or allergic rhinitis (hay fever). Hence, the demand for bronchodilators is growing.

Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-Commerce)

The hospital segment is projected to account for 60% share of the global adrenergic drug market during the forecast period. Adrenergic drug is usually prescribed by doctors in the hospital and additionally, in some cases the patients are kept under observation after the consumption of this drug. Hence, most people prefer hospitals for the distribution for this drug. Furthermore, most of the medications are made available only in the hospital pharmacy. Hence, consumers might be entangled to purchase the same from there. Also, the price of various medications is hospitals especially the government is relatively low.

Our in-depth analysis of the global adrenergic drug market includes the following segments: